Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally advanced pancreatic cancer

Davendra P.S. Sohal, James M. Metz, Weijing Sun, Bruce J. Giantonio, John P. Plastaras, Gregory Ginsberg, Michael L. Kochman, Ursina R. Teitelbaum, Kathleen Harlacker, Daniel F. Heitjan, Michael D. Feldman, Jeffrey A. Drebin, Peter J. O'Dwyer

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Purpose: Platinum compounds or bevacizumab, in combination with gemcitabine, achieved good response rates in early studies in advanced pancreatic cancer. This prompted an evaluation of an aggressive approach to allow better local control and resectability in locally advanced disease. Methods: We piloted a combination of gemcitabine/oxaliplatin/bevacizumab Q2w for four cycles, followed by oxaliplatin and bevacizumab added to infusional 5-FU and radiotherapy, in patients with locally advanced pancreatic cancer. Results: Nineteen patients were treated, of whom 17 completed the protocol-specified treatment. Median age was 60 years. Fifteen had unresectable, and four had borderline resectable disease. Toxicity of chemotherapy was moderate: grade III neutropenia (5) and grade I/II nausea, vomiting, fatigue, and neuropathy. During chemoradiation, major grade III toxicities were nausea and vomiting (3 each). One patient had intractable pain early on, necessitating treatment cessation. Response rate for 18 evaluable patients was 11 % (by RECIST); five patients (4 inoperable, 1 borderline, 26 %) went on to have surgery. One-year overall survival was 58 % and progression-free survival was 37 %. Conclusions: This combination, associated with higher response rates in metastatic disease, had a lower than expected response rate in primary tumors. Although tolerable, our approach failed to affect clinical outcomes meaningfully.

Original languageEnglish (US)
Pages (from-to)1485-1491
Number of pages7
JournalCancer Chemotherapy and Pharmacology
Volume71
Issue number6
DOIs
StatePublished - Jun 1 2013

Fingerprint

oxaliplatin
gemcitabine
Radiotherapy
Pancreatic Neoplasms
Fluorouracil
Toxicity
Platinum Compounds
Chemotherapy
Nausea
Vomiting
Surgery
Tumors
Intractable Pain
Withholding Treatment
Fatigue of materials
Clinical Protocols
Neutropenia
Disease-Free Survival
Fatigue
Bevacizumab

Keywords

  • Bevacizumab
  • Chemoradiation
  • Locally advanced
  • Pancreatic cancer

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally advanced pancreatic cancer. / Sohal, Davendra P.S.; Metz, James M.; Sun, Weijing; Giantonio, Bruce J.; Plastaras, John P.; Ginsberg, Gregory; Kochman, Michael L.; Teitelbaum, Ursina R.; Harlacker, Kathleen; Heitjan, Daniel F.; Feldman, Michael D.; Drebin, Jeffrey A.; O'Dwyer, Peter J.

In: Cancer Chemotherapy and Pharmacology, Vol. 71, No. 6, 01.06.2013, p. 1485-1491.

Research output: Contribution to journalArticle

Sohal, DPS, Metz, JM, Sun, W, Giantonio, BJ, Plastaras, JP, Ginsberg, G, Kochman, ML, Teitelbaum, UR, Harlacker, K, Heitjan, DF, Feldman, MD, Drebin, JA & O'Dwyer, PJ 2013, 'Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally advanced pancreatic cancer', Cancer Chemotherapy and Pharmacology, vol. 71, no. 6, pp. 1485-1491. https://doi.org/10.1007/s00280-013-2147-4
Sohal, Davendra P.S. ; Metz, James M. ; Sun, Weijing ; Giantonio, Bruce J. ; Plastaras, John P. ; Ginsberg, Gregory ; Kochman, Michael L. ; Teitelbaum, Ursina R. ; Harlacker, Kathleen ; Heitjan, Daniel F. ; Feldman, Michael D. ; Drebin, Jeffrey A. ; O'Dwyer, Peter J. / Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally advanced pancreatic cancer. In: Cancer Chemotherapy and Pharmacology. 2013 ; Vol. 71, No. 6. pp. 1485-1491.
@article{d7dfe0cbfbc3486b9424a3b4b4b2ce25,
title = "Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally advanced pancreatic cancer",
abstract = "Purpose: Platinum compounds or bevacizumab, in combination with gemcitabine, achieved good response rates in early studies in advanced pancreatic cancer. This prompted an evaluation of an aggressive approach to allow better local control and resectability in locally advanced disease. Methods: We piloted a combination of gemcitabine/oxaliplatin/bevacizumab Q2w for four cycles, followed by oxaliplatin and bevacizumab added to infusional 5-FU and radiotherapy, in patients with locally advanced pancreatic cancer. Results: Nineteen patients were treated, of whom 17 completed the protocol-specified treatment. Median age was 60 years. Fifteen had unresectable, and four had borderline resectable disease. Toxicity of chemotherapy was moderate: grade III neutropenia (5) and grade I/II nausea, vomiting, fatigue, and neuropathy. During chemoradiation, major grade III toxicities were nausea and vomiting (3 each). One patient had intractable pain early on, necessitating treatment cessation. Response rate for 18 evaluable patients was 11 {\%} (by RECIST); five patients (4 inoperable, 1 borderline, 26 {\%}) went on to have surgery. One-year overall survival was 58 {\%} and progression-free survival was 37 {\%}. Conclusions: This combination, associated with higher response rates in metastatic disease, had a lower than expected response rate in primary tumors. Although tolerable, our approach failed to affect clinical outcomes meaningfully.",
keywords = "Bevacizumab, Chemoradiation, Locally advanced, Pancreatic cancer",
author = "Sohal, {Davendra P.S.} and Metz, {James M.} and Weijing Sun and Giantonio, {Bruce J.} and Plastaras, {John P.} and Gregory Ginsberg and Kochman, {Michael L.} and Teitelbaum, {Ursina R.} and Kathleen Harlacker and Heitjan, {Daniel F.} and Feldman, {Michael D.} and Drebin, {Jeffrey A.} and O'Dwyer, {Peter J.}",
year = "2013",
month = "6",
day = "1",
doi = "10.1007/s00280-013-2147-4",
language = "English (US)",
volume = "71",
pages = "1485--1491",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally advanced pancreatic cancer

AU - Sohal, Davendra P.S.

AU - Metz, James M.

AU - Sun, Weijing

AU - Giantonio, Bruce J.

AU - Plastaras, John P.

AU - Ginsberg, Gregory

AU - Kochman, Michael L.

AU - Teitelbaum, Ursina R.

AU - Harlacker, Kathleen

AU - Heitjan, Daniel F.

AU - Feldman, Michael D.

AU - Drebin, Jeffrey A.

AU - O'Dwyer, Peter J.

PY - 2013/6/1

Y1 - 2013/6/1

N2 - Purpose: Platinum compounds or bevacizumab, in combination with gemcitabine, achieved good response rates in early studies in advanced pancreatic cancer. This prompted an evaluation of an aggressive approach to allow better local control and resectability in locally advanced disease. Methods: We piloted a combination of gemcitabine/oxaliplatin/bevacizumab Q2w for four cycles, followed by oxaliplatin and bevacizumab added to infusional 5-FU and radiotherapy, in patients with locally advanced pancreatic cancer. Results: Nineteen patients were treated, of whom 17 completed the protocol-specified treatment. Median age was 60 years. Fifteen had unresectable, and four had borderline resectable disease. Toxicity of chemotherapy was moderate: grade III neutropenia (5) and grade I/II nausea, vomiting, fatigue, and neuropathy. During chemoradiation, major grade III toxicities were nausea and vomiting (3 each). One patient had intractable pain early on, necessitating treatment cessation. Response rate for 18 evaluable patients was 11 % (by RECIST); five patients (4 inoperable, 1 borderline, 26 %) went on to have surgery. One-year overall survival was 58 % and progression-free survival was 37 %. Conclusions: This combination, associated with higher response rates in metastatic disease, had a lower than expected response rate in primary tumors. Although tolerable, our approach failed to affect clinical outcomes meaningfully.

AB - Purpose: Platinum compounds or bevacizumab, in combination with gemcitabine, achieved good response rates in early studies in advanced pancreatic cancer. This prompted an evaluation of an aggressive approach to allow better local control and resectability in locally advanced disease. Methods: We piloted a combination of gemcitabine/oxaliplatin/bevacizumab Q2w for four cycles, followed by oxaliplatin and bevacizumab added to infusional 5-FU and radiotherapy, in patients with locally advanced pancreatic cancer. Results: Nineteen patients were treated, of whom 17 completed the protocol-specified treatment. Median age was 60 years. Fifteen had unresectable, and four had borderline resectable disease. Toxicity of chemotherapy was moderate: grade III neutropenia (5) and grade I/II nausea, vomiting, fatigue, and neuropathy. During chemoradiation, major grade III toxicities were nausea and vomiting (3 each). One patient had intractable pain early on, necessitating treatment cessation. Response rate for 18 evaluable patients was 11 % (by RECIST); five patients (4 inoperable, 1 borderline, 26 %) went on to have surgery. One-year overall survival was 58 % and progression-free survival was 37 %. Conclusions: This combination, associated with higher response rates in metastatic disease, had a lower than expected response rate in primary tumors. Although tolerable, our approach failed to affect clinical outcomes meaningfully.

KW - Bevacizumab

KW - Chemoradiation

KW - Locally advanced

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=84878627817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878627817&partnerID=8YFLogxK

U2 - 10.1007/s00280-013-2147-4

DO - 10.1007/s00280-013-2147-4

M3 - Article

C2 - 23532207

AN - SCOPUS:84878627817

VL - 71

SP - 1485

EP - 1491

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 6

ER -